Sarepta Therapeutics Inc (NASDAQ:SRPT) – Leerink Swann raised their FY2019 earnings estimates for Sarepta Therapeutics in a research note issued on Monday. Leerink Swann analyst J. Schwartz now anticipates that the biotechnology company will post earnings per share of $0.40 for the year, up from their prior forecast of $0.20. Leerink Swann has a “Positive” rating and a $92.00 price target on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ FY2020 earnings at $2.75 EPS.
A number of other equities research analysts have also issued reports on the company. Zacks Investment Research lowered Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. HC Wainwright started coverage on Sarepta Therapeutics in a research report on Friday, December 1st. They issued a “buy” rating and a $75.00 price objective for the company. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Royal Bank of Canada started coverage on Sarepta Therapeutics in a research report on Monday, January 22nd. They issued an “outperform” rating for the company. Finally, UBS reiterated an “outperform” rating and issued a $56.51 price objective (down from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics currently has an average rating of “Buy” and an average price target of $75.31.
Sarepta Therapeutics (SRPT) traded down $0.30 during mid-day trading on Thursday, hitting $80.92. The stock had a trading volume of 1,846,515 shares, compared to its average volume of 1,441,733. The company has a quick ratio of 12.96, a current ratio of 13.91 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $5,277.54, a price-to-earnings ratio of -101.15 and a beta of 1.52. Sarepta Therapeutics has a 1-year low of $28.14 and a 1-year high of $84.37.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). The company had revenue of $57.30 million during the quarter, compared to analysts’ expectations of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. Sarepta Therapeutics’s revenue for the quarter was up 961.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.71) earnings per share.
Large investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 977 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its stake in Sarepta Therapeutics by 140.9% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 2,493 shares in the last quarter. Prentiss Smith & Co. Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter worth $199,000. Brighton Jones LLC acquired a new position in Sarepta Therapeutics during the third quarter worth $211,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Sarepta Therapeutics during the fourth quarter worth $217,000. Institutional investors own 85.14% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “FY2019 EPS Estimates for Sarepta Therapeutics Inc (SRPT) Lifted by Leerink Swann” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/17/fy2019-eps-estimates-for-sarepta-therapeutics-inc-srpt-lifted-by-leerink-swann.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.